ReviewAntibiotics (Basel, Switzerland)2023
Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future.
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Oleic Acid-Modified Oligochitosan Nanoparticles Preserve Bacteriophage Lytic Activity against ClinicalACS omega · 2026Article
- A DNA Tetrahedron-Delivered miR-17-5p mimic exerts dual anti-inflammatory and Anti-Non-coding RNA research · 2026Article
- Clinical Outcomes and Healthcare Resource Utilization Results Among Hospitalized Adults with Cystic Fibrosis Treated with Ceftolozane/Tazobactam: A SPECTRA Real-World Subgroup Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Review
- Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent Fluorothiazinone.The Journal of antibiotics · 2026Article
- Healthcare resource utilization and readmission outcomes in patients treated with ceftolozane/tazobactam: real-world insights from the multinational SPECTRA study.JAC-antimicrobial resistance · 2026Article
- Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.Annals of the American Thoracic Society · 2026Article
- Contribution of two-component regulatory systems to the acute-to-chronic infection transition ofJournal of bacteriology · 2026Review
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Revolutionizing Antibiotic Delivery: Harnessing 3D-Printing Technology to Combat Bacterial Resistance.Current pharmaceutical design · 2026Review
- Impact of Host and Bacterial Metabolism on Antibiotic Susceptibility.Biochemistry · 2025Review
- In vitro Antibiotic Susceptibility of Bacterial Isolates from Polish patients with Cystic Fibrosis: A Non-Interventional Study.Polish journal of microbiology · 2025Article
- Evolving Cystic Fibrosis Care: Lung Immunology and Emerging Health Challenges in the Era of CFTR Modulators.Biomolecules · 2025Review
- Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon.BMC microbiology · 2025Article
- Pathogen Partnerships or Power Struggles? Pseudomonas aeruginosa, and Staphylococcus aureus Dynamics in Cystic Fibrosis.Current microbiology · 2025Article
- Broad-spectrum antimicrobial properties of linalool: supporting its pharmacological use in chronic wound infections by pathogens within the ESKAPE group and polymicrobial biofilms.World journal of microbiology & biotechnology · 2025Article
- Menadione as Antibiotic Adjuvant AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Mucosal-adapted bacteriophages as a preventive strategy for a lethal Pseudomonas aeruginosa challenge in mice.Communications biology · 2025Article
- Policy in practice: Cystic Fibrosis Australia and Phage Australia surveys: understanding clinical needs and attitudes towards phage therapy in the cystic fibrosis community.Sustainable microbiology · 2025Article
- Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cystic fibrosis (CF) are repeatedly exposed to antibiotics, especially during the pulmonary exacerbations of the disease. However, the available therapeutic strategies are frequently inadequate to eradicate the involved pathogens and most importantly, facilitate the development of antimicrobial resistance (AMR). The evaluation of AMR is demanding; conventional culture-based susceptibility-testing techniques cannot account for the lung microenvironment and/or the adaptive mechanisms developed by the pathogens, such as biofilm formation. Moreover, features linked to modified pharmaco-kinetics and pulmonary parenchyma penetration make the dosing of antibiotics even more challenging. In this review, we present the existing knowledge regarding AMR in CF, we shortly review the existing therapeutic strategies, and we discuss the future directions of antimicrobial stewardship. Due to the increasing difficulty in eradicating strains that develop AMR, the appropriate management should rely on targeting the underlying resistance mechanisms; thus, the interest in novel, molecular-based diagnostic tools, such as metagenomic sequencing and next-generation transcriptomics, has increased exponentially. Moreover, since the development of new antibiotics has a slow pace, the design of effective treatment strategies to eradicate persistent infections represents an urgency that requires consorted work. In this regard, both the management and monitoring of antibiotics usage are obligatory and more relevant than ever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.